EN DE
Watch Knight Therapeutics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Knight Therapeutics Inc. (GUD) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Knight Therapeutics Inc. stock C$18.36, price C$12.05, upside +52.4%, quality 66 out of 100. Rating: strongly undervalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA

KT Knight Therapeutics Inc. logo Some data Nov 12, 2026

Knight Therapeutics Inc.

GUD · TO

Cheap (34% below fair value), solid company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value C$18.36 · Strongly undervalued 
Quality 66/100 
Rising price (uptrend) 
Low debt 
Generates free cash flow 
Ranks above peers (8/13) 
Mixed Growth (revenue 5y +17.7 %/yr in CAD) 
Thin margins · 2.8% net margin (TTM) 
Some data 
Costs 75 times its yearly profit. 
Changed on Nov 7: C$15.76 → C$18.36 
Narrow moat 28/100
Watch Knight Therapeutics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$12.05 C$4.35 Fair Value C$18.36 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range C$4.35 – C$12.05 · fair‑value band C$9.11 – C$26.41 · the C$12.05 price screens below the C$18.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Knight Therapeutics in your weekly email

Every Wednesday you see whether Knight Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America.

Show moreShow less

The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease.

In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.

Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive.

Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Stock analysis

Knight Therapeutics Inc. (GUD) currently trades at C$12.05, while our model-based Fair Value estimate is C$18.36, implying the stock looks roughly 34% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of C$19.23 per share, and 8 of the 11 models we run sit above the C$12.05 price.

Bear case: the Multiples group reads lowest at C$8.38, and 3 of the 11 models stay below the price. Data coverage for this calculation is medium.

Scenario range: C$9.11 (bear) to C$26.41 (bull), the price of C$12.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Knight Therapeutics Inc. reported revenue of C$450M in FY2025 versus C$243M in FY2021, a compound +16.6%/yr. Reported net income was −C$5.4M in FY2025.

Key figures

Market cap C$1.2B (≈ $830M) Small · P/E ratio 75.3 · P/S ratio 2.10 · EPS (TTM) C$0.1600 · Net margin 2.8% · Return on equity 2.1% · Return on assets (EBIT) −0.1% (5-year average) · Operating margin 4.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and 109% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 52%, GUD screens cheaper than that median.

Fair Value models

Bear C$9.11 Fair Value C$18.36 Bull C$26.41
Price C$12.05 · Upside +52.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (C$0.1390 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF C$12.49 C$19.00 C$39.19 74
Growth DCF C$11.74 C$21.91 C$38.23 73
5Y EBITDA Exit C$8.06 C$13.04 C$22.77 70
All 11 models by family
DCF Models
FCF DCF C$12.49 C$19.00 C$39.19 74
Owner Earnings C$9.11 C$19.76 C$41.11 69
5Y Revenue Exit C$8.77 C$14.49 C$26.41 67
5Y EBITDA Exit C$8.06 C$13.04 C$22.77 70
10Y Revenue Exit C$9.75 C$19.86 C$25.92 64
10Y EBITDA Exit C$9.52 C$18.36 C$32.99 63
Multiples
EV/EBITDA C$5.79 C$7.73 C$9.67 67
EV/Revenue C$6.32 C$9.03 C$11.75 53
Asset-Based
NCAV (Graham) C$0.7800 C$1.18 C$1.47 55
Growth DCF
Growth DCF C$11.74 C$21.91 C$38.23 73
Rev-Margin DCF C$9.63 C$16.54 C$31.04 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 66/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 75
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 93
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 100
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Start year 2020 (pandemic). Over 10 years: +83.5% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.7% (2020) → −0.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about +4.0% a year for the price and +3.8% for the forecasts.
Forecast 2026 (sales)+25.6%
Forecast 2027 (sales)+1.6%
Projected 2028 (sales)+1.6%
Projected 2029 (sales)+1.7%
Projected 2030 (sales)+1.7%

Watch GUD, get fair value alerts →

Compare Knight Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside +52.4% · Top 25%
Profitability
Return on equity (12 months) 2.1% · Below median
Return on assets −0.5% · Below median
Net margin (12 months) 2.8% · Below median
Operating margin (12 months) 4.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 13.3% · Above median
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 75.3× · Priciest 25%
P/B 1.54× · Cheaper than median
P/S (12 months) 2.10× · Cheaper than median
Price / free cash flow (fiscal year) 17.3× · Cheaper than median
EV/EBITDA 13.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 18
FUTURE (revenue growth)67 · sector 25
PAST (return on equity)8 · sector 25
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.96 $113.53 +37% vs GUD
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.93 ¥53.04 +11% vs GUD
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,885 ₹1,983 +5% vs GUD
Haleon plc HLN $9.09 $8.62 −5% vs GUD
Merck KGaA MRK €148.15 €108.83 −27% vs GUD
Galderma Group GALD CHF 194.40 CHF 111.92 −42% vs GUD
Takeda Pharmaceutical Company TAK $21.12 $11.34 −46% vs GUD
Teva Pharmaceutical Industries Limited TEVA $43.65 $20.74 −52% vs GUD
Sandoz Group SDZ CHF 86.90 CHF 40.54 −53% vs GUD
Divi's Laboratories Limited DIVISLAB ₹11,485 ₹1,567 −86% vs GUD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Knight Therapeutics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Knight Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/GUD

Frequently asked questions

Is Knight Therapeutics Inc. (GUD) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of C$18.36 versus a price of C$12.05, about +52% upside (undervalued).
What is the fair value of GUD?
Our model-based fair value for Knight Therapeutics Inc. is C$18.36 (as of Nov 12, 2026), built from audited fundamentals. The current price: C$12.05.
What is the quality score of GUD?
Knight Therapeutics Inc. has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Knight Therapeutics Inc. (GUD)?
Our model-based price target is the fair value of C$18.36 (as of Nov 12, 2026) from 11 valuation models. Cautious scenario C$9.11, optimistic scenario C$26.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Knight Therapeutics Inc. stock forecast for 2026?
Our models put fair value at C$18.36, about +52% upside versus a price of C$12.05 (undervalued). Cautious scenario C$9.11, optimistic scenario C$26.41. The calculation is refreshed regularly with new filings.
What is the revenue of Knight Therapeutics Inc. (GUD)?
Knight Therapeutics Inc. reported trailing-twelve-month revenue of about C$563M (latest available figure, as of Nov 12, 2026).
What growth is priced into Knight Therapeutics Inc. (GUD)?
For today's price to be fair in a discounted-cash-flow model, Knight Therapeutics Inc. would have to grow free cash flow by +6.2 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.7 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of GUD use?
Our models discount Knight Therapeutics Inc. at 9.6 %: a base by market capitalisation (small), damped by beta 0.02, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Knight Therapeutics Inc. that is +6.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Knight Therapeutics Inc. (GUD) delivered so far?
Over the past 5 years revenue at Knight Therapeutics Inc. grew +17.7 % a year. The price currently implies free-cash-flow growth of +6.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Knight Therapeutics Inc. (GUD) growing?
The median revenue growth in the sector is +1.6 % a year. That is the yardstick for the growth priced into Knight Therapeutics Inc. (+6.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Knight Therapeutics Inc. (GUD)?
The free-cash-flow yield on the price is 5.78 %: that much free cash flow Knight Therapeutics Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Knight Therapeutics Inc. (GUD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Knight Therapeutics Inc. it is C$18.36 per share (as of Nov 12, 2026), against a price of C$12.05. It is the blended result of 11 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Knight Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 12, 2026, GUD trades below its calculated fair value: price C$12.05, fair value C$18.36, a gap of about +52% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GUD?
No. The price is what the market pays today (C$12.05); the fair value is what the company's own numbers justify (C$18.36). For Knight Therapeutics Inc. the two are C$6.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Knight Therapeutics Inc. worth?
The market values Knight Therapeutics Inc. at about C$1.2B (market capitalisation, as of Nov 12, 2026). Per share that is C$12.05; our models calculate a fair value of C$18.36 per share.
What do the bullish and bearish scenarios say about GUD?
Our models span a range for Knight Therapeutics Inc.: cautious scenario C$9.11, base C$18.36, optimistic C$26.41 per share (as of Nov 12, 2026, price C$12.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GUD?
Knight Therapeutics Inc. trades at a price-to-earnings ratio of 75.3 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$18.36 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2016 to 2024), reported earnings: 69.1. Other multiples: P/B 1.5, P/S 2.1, EV/EBITDA 13.0.
How solid is the balance sheet of Knight Therapeutics Inc. (GUD)?
Balance-sheet figures for Knight Therapeutics Inc. (as of Nov 12, 2026): return on equity 2.1%, debt of 0.07 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is GUD from its 52-week high?
Knight Therapeutics Inc. trades at C$12.05, at its 52-week high of C$12.05 and 109% above the low of C$5.76 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of C$18.36 is for.
Which stocks are comparable to Knight Therapeutics Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Knight Therapeutics Inc. stock attractive at the current price?
The data as of Nov 12, 2026: price C$12.05, calculated fair value C$18.36 (+52%), Quality Score 66/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GUD calculated?
We run Knight Therapeutics Inc. through 11 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of C$18.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Knight Therapeutics Inc. currently trades 34% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Knight Therapeutics Inc. (GUD)?
The closing price on Nov 12, 2026 was C$12.05. Our model-based fair value is C$18.36, about +52% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Knight Therapeutics Inc. right now?
The model range is unusually wide (C$9.11 to C$26.41). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Knight Therapeutics Inc.

How large is the market capitalisation of Knight Therapeutics Inc. (GUD)?
The market capitalisation of Knight Therapeutics Inc. is C$1.2B (≈ $830M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Knight Therapeutics Inc. (GUD)?
The price-to-sales ratio of Knight Therapeutics Inc. is 2.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Knight Therapeutics Inc. (GUD)?
Earnings per share at Knight Therapeutics Inc. are C$0.1600 (price ÷ EPS = P/E 75.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Knight Therapeutics Inc. (GUD)?
The net margin of Knight Therapeutics Inc. is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Knight Therapeutics Inc. (GUD)?
The return on equity (ROE) of Knight Therapeutics Inc. is 2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Knight Therapeutics Inc. (GUD)?
On an EBIT basis the return on assets of Knight Therapeutics Inc. is −0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Knight Therapeutics Inc. (GUD)?
The operating margin of Knight Therapeutics Inc. is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Knight Therapeutics Inc. (GUD)?
Revenue at Knight Therapeutics Inc. is growing +13.3% versus a year earlier (3y avg +15.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Knight Therapeutics Inc. (GUD)?
Earnings per share at Knight Therapeutics Inc. are growing +550% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Knight Therapeutics Inc. (GUD) carry?
The net debt of Knight Therapeutics Inc. is C$1.5M (fiscal year 2025, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Knight Therapeutics Inc. in the live analysis

One click puts Knight Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.